Jd. Hainsworth et al., PHASE-II RANDOMIZED STUDY OF CISPLATIN PLUS ETOPOSIDE PHOSPHATE OR ETOPOSIDE IN THE TREATMENT OF SMALL-CELL LUNG-CANCER, Journal of clinical oncology, 13(6), 1995, pp. 1436-1442
Purpose: This randomized phase II study evaluated the efficacy toxicit
y of etoposide phosphate when used in combination with cisplatin in th
e treatment of smalt-cell lung cancer. Patients and Methods: Patients
with previously untreated small-cell lung cancer were randomized to re
ceive cisplatin in combination With either etoposide or etoposide phos
phate. Molar-equivalent doses of etoposide and etoposide phosphate wer
e used, Response rate, time to progression, survival, and toxicity wer
e compared, Results: Major response rates with etoposide phosphate and
etoposide were 61% (95% confidence interval, 55% to 67%) and 58% (95%
confidence interval, 52% to 64%), respectively (P = .85). No signific
ant differences in median time to progression or survival were Observe
d in patients who recieved etoposide phosphate versus etoposide. Grade
3 and 4 leukopenia occurred in 63% of patients who received etoposide
phosphate compared with 77% who received etoposide (P = .16). Conclus
ion: The combination of etoposide phosphate and cisplatin is effective
in the treatment of small-cell lung cancer, and can be administered w
ith acceptable toxicity. Although this study was not designed to be a
formal comparative trial, the efficacy and toxicity observed with this
regimen were found to be similar to a standard etoposide/cisplatin re
gimen, using molar-equivalent etoposide doses. Because of its greater
ease of administration, etoposide phosphate is preferrable to etoposid
e for routine clinical use. (C) 1995 by American Society of Clinical O
ncology.